黄葵胶囊联合缬沙坦治疗早期糖尿病肾病的临床疗效及安全性观察

目的]观察早期糖尿病肾病患者口服黄葵胶囊联合缬沙坦胶囊治疗的临床疗效及药物安全性。方法]选取早期糖尿病肾病患者80例,并随机分为观察组与对照组,每组40例。两组患者均给与常规基础治疗,观察组患者给与口服黄葵胶囊联合缬沙坦胶囊进行治疗,对照组患者给与缬沙坦胶囊进行治疗,连续用药疗程均为3个月。比较两组患者治疗前后尿微量白蛋白排泄率(UAER)、血清尿素氮(BUN)及肌酐(Scr)的变化等,进行对比分析。结果]观察组治疗前后UAER、Scr、BUN比较,差异有统计学意义;对照组治疗前后UAER、BUN、Scr比较,差异有统计学意义。观察组治疗后UAER较对照组降低更为明显(P0.05),两组治疗后BUN和Scr下降程度差异不明显(P0.05)。结论]使用黄葵胶囊联合缬沙坦胶囊治疗早期糖尿病肾病,两者具有较好的协同作用。

Observation on clinical effect and safety on early diabetic nephropathy treated with ambrette capsule combined valsartan

Objective] To observe the clinical curative effect and safety of ambrette capsules combined valsartan capsules in treating early diabetic nephropathy patients.Methods] Eighty patients with early diabetic nephropathy were selected and randomly divided into observation group and control group, 40 cases in each group. Two groups of patients were given the conventional foundation treatment. The observation group of patients were given oral ambrette capsules combined valsartan capsules treatment. Patients in control group were given valsartan capsules treatment. All groups were given drug treatment for 3 months continuously. The level of urine trace albumin excretion rate (UAER), serum urea nitrogen (BUN) and creatinine (Scr) changes between two groups of patients before and after treatment would be compared and analyzed.Results] Compared among the UAER, BUN and Scr of observation group before and after treatment,the difference was statistically significant. Compared among the UAER, BUN, Scr of control group before and after treatment,the difference was statistically significant. The UAER of observation group is decreased more significantly than the control group(P<0.05) after treatment. The degree of decrease in BUN and Scr between two groups after treatment is not obvious (P>0.05).Conclusion] Using ambrette capsules combined valsartan capsules treating early diabetic nephropathy, both had good synergetic effect.